1 / 5

Spinal Muscular Atrophy Phase 3 Candidate ISIS-SMNRx Expected to Reach USD 0.47 Billion in Sales in the U.S

Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness analysis considers various factors such as patient population, drug pricing policies, regulatory restrictions, current competition intensity, and current state of healthcare sector for assessing the potential of each geographical market.<br>

kksingha
Download Presentation

Spinal Muscular Atrophy Phase 3 Candidate ISIS-SMNRx Expected to Reach USD 0.47 Billion in Sales in the U.S

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023 Published Date 16-Oct-2015 44 Page Report Request Sample Buy Now Press Release Spinal Muscular Atrophy Phase 3 Candidate ISIS-SMNRx Expected to Reach USD 0.47 Billion in Sales in the U.S:Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Spinal Muscular Atrophy Market REPORT DESCRIPTION Spinal Muscular Atrophy Market-Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023 Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness analysis considers various factors such as patient population, drug pricing policies, regulatory restrictions, current competition intensity, and current state of healthcare sector for assessing the potential of each geographical market. Browse the full report at http://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html In the pipeline analysis of spinal muscular atrophy (SMA) market report, market analysis and forecast has been provided for late stage (phase 3) candidates, while also includes thorough qualitative information for other candidates in early stage (phase 1 and phase 2). ISIS-SMNRx by Isis Pharmaceuticals is presently the only late stage candidate in spinal muscular atrophy pipeline, while three drugs are currently in phase 2 and three others in phase 1. These include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039. The report also mentions some of the potential preclinical candidates in the spinal muscular atrophy pipeline. The pipeline analysis of spinal muscular atrophy (SMA) market report provides overview of the clinical trials, and its current status for each drug candidate for treatment of spinal muscular atrophy. Details on mergers, acquisitions, licensing agreements, and other collaborative agreements, updated on regulatory policies, and expected study completion are also mentioned in the report. Market estimation and forecast for phase 3 drugs for treatment of spinal muscular atrophy has been provided from the expected year of drug approval, till 2023 (in USD Million) for the United States. Related & Recently Published Report by Transparency Market Research Organ Transplant Immunosuppressant Drugs Market : http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html Pipeline analysis of late stage (phase 3) drugs for treatment of spinal muscular atrophy adopts patient based approach, in which actual patient population that can be targeted by the new drug is considered to arrive at probable sales of the drug in the launch year. Forecast model considers various macro- as well as micro-economic factors such as drug efficiency, side effects, prevalence and incidence rate, impact of regulatory policies, impact of competitor drugs and generic competition (if applicable) and pipeline status. The report collates information from various government as well as corporate sources such as Europe and the U.S. clinical trial registries, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), CureSMA, Families of SMA, PubMed, company press releases, annual reports and investor presentations. The analysis also considers inputs from industry experts and key opinion leaders with expertise in rare disease drug discovery, and marketing and sales experts. 2 Transparency Market Research

  3. Spinal Muscular Atrophy Market Latest Press Release Of This Report: http://www.transparencymarketresearch.com/pressrelease/spinal-muscular- atrophy-market.htm Key players with potential candidates in clinical trials for treatment of spinal muscular atrophy have been profiled in the report. These include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments. Get Sample Report Copy with TOC and Market Research : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7187 TABLE OF CONTENT Chapter 1 Introduction 1.1 Report Description 1.2 Research Methodology 1.3 Market Segmentation 1.4 Assumptions Chapter 2 Executive Summary 2.1 Pipeline Analysis: Spinal Muscular Atrophy- Market Snapshot Chapter 3 Pipeline Analysis: Spinal Muscular Atrophy Market Overview 3.1 Market Definition and Overview 3.2 Current Treatment for Spinal Muscular Atrophy 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3 Market Attractiveness Analysis 3 Transparency Market Research

  4. Spinal Muscular Atrophy Market Chapter 4 : Pipeline Analysis: Spinal Muscular Atrophy 4.1 Spinal Muscular Atrophy: Pipeline Overview 4.2 Late Stage Candidates (Phase 3) 4.2.1 ISIS-SMN Rx 4.3 Early Stage Candidates (Phase 1 and Phase 2) 4.3.1 Olesoxime (TRO19622) 4.3.2 LMI070 4.3.3 RO6885247 4.3.4 CK-2127107 4.3.5 scAAV9.CB.SMN 4.3.6 RG3039 Chapter 5 Recommendation Chapter 6 Company Profiles 6.1 AveXis, Inc. 6.2 Cytokinetics, Inc. 6.3 F. Hoffmann-La Roche Ltd. 6.4 Novartis AG 6.5 Isis Pharmaceuticals, Inc. Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. 4 Transparency Market Research

  5. Spinal Muscular Atrophy Market We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : https://keshabblog.wordpress.com 5 Transparency Market Research

More Related